## Magnus Bäck

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7589796/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Incidence, associated outcomes, and predictors of upper gastrointestinal bleeding following acute myocardial infarction: a SWEDEHEART-based nationwide cohort study. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 483-491.	1.4	25
2	Aortic valve calcification score utility extended to moderate aortic stenosis. European Heart Journal Cardiovascular Imaging, 2022, 23, 185-187.	0.5	0
3	Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. European Heart Journal, 2022, 43,	1.0	83
4	Epidemiology of Aortic Stenosis/Aortic Valve Replacement (from the Nationwide Swedish Renal) Tj ETQq0 0 0 rgB	[  Overlocl	R 10 Tf 50 6

5	Plasma Lipoprotein(a) measured in routine clinical care and the association with incident calcified aortic valve stenosis during a 14-year observational period. Atherosclerosis, 2022, 349, 175-182.	0.4	7
6	Arterial Stiffness in Aortic Stenosis and the Impact of Aortic Valve Replacement. Vascular Health and Risk Management, 2022, Volume 18, 117-122.	1.0	9
7	Fatty acid desaturase genetic variations and dietary omega-3 fatty acid intake associate with arterial stiffness. European Heart Journal Open, 2022, 2, .	0.9	6
8	Vascular smooth muscle cell dysfunction: role in arterial stiffening and cardiovascular disease. , 2022, , 341-357.		0
9	The resolvin D2 – GPR18 axis is expressed in human coronary atherosclerosis and transduces atheroprotection in apolipoprotein E deficient mice. Biochemical Pharmacology, 2022, 201, 115075.	2.0	18
10	Calcific aortic valve stenosis and COVID-19: clinical management, valvular damage, and pathophysiological mechanisms. Cardiology Plus, 2022, 7, 3-11.	0.2	0
11	Resolution of HeartÂFailure Inflammation. JACC Basic To Translational Science, 2022, 7, 561-562.	1.9	0
12	Endothelial function in cardiovascular medicine: a consensus paper of the European Society of Cardiology Working Groups on Atherosclerosis and Vascular Biology, Aorta and Peripheral Vascular Diseases, Coronary Pathophysiology and Microcirculation, and Thrombosis. Cardiovascular Research, 2021, 117, 29-42.	1.8	164
13	Helicobacter pylori screening in clinical routine during hospitalization for acute myocardial infarction. American Heart Journal, 2021, 231, 105-109.	1.2	14
14	Echocardiographic speckle tracking provides incremental value for left atrial function in patients with paroxysmal atrial fibrillation. European Heart Journal Cardiovascular Imaging, 2021, 22, .	0.5	0
15	Elevated echocardiographic markers for left atrial stiffness and fibrosis in patients with paroxysmal atrial fibrillation. European Heart Journal Cardiovascular Imaging, 2021, 22, .	0.5	0
16	Pro-resolving Mediators. , 2021, , 1-6.		0
17	From organic and inorganic phosphates to valvular and vascular calcifications. Cardiovascular Research, 2021, 117, 2016-2029.	1.8	35
18	Telomere Length in Valve Tissue Is Shorter in Individuals With Aortic Stenosis and in Calcified Valve Areas. Frontiers in Cell and Developmental Biology, 2021, 9, 618335.	1.8	5

#	Article	IF	CITATIONS
19	Fatty acids and aortic valve stenosis. Kardiologia Polska, 2021, 79, 614-621.	0.3	7
20	Artificial Intelligence Models Reveal Sex-Specific Gene Expression in Aortic Valve Calcification. JACC Basic To Translational Science, 2021, 6, 403-412.	1.9	24
21	Dose-Dependent Risk Reduction for Myocardial Infarction with Eicosapentaenoic Acid: a Meta-analysis and Meta-regression Including the STRENGTH Trial. Cardiovascular Drugs and Therapy, 2021, 35, 1079-1081.	1.3	11
22	Formylpeptide receptors in GtoPdb v.2021.2. IUPHAR/BPS Guide To Pharmacology CITE, 2021, 2021, .	0.2	1
23	Open Up your Science in <i>EHJ Open</i> . European Heart Journal Open, 2021, 1, .	0.9	1
24	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2021, 42, 3227-3337.	1.0	2,517
25	von Willebrand factor's vascular crossroad. Cardiovascular Research, 2021, , .	1.8	1
26	The double-action of hydrogen peroxide on the oxidative atherosclerosis battlefield. Atherosclerosis, 2021, 331, 28-30.	0.4	4
27	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G proteinâ€coupled receptors. British Journal of Pharmacology, 2021, 178, S27-S156.	2.7	337
28	Palmdelphin Regulates Nuclear Resilience to Mechanical Stress in the Endothelium. Circulation, 2021, 144, 1629-1645.	1.6	13
29	Unfolding <i>EHJ Open</i> . European Heart Journal Open, 2021, 1, .	0.9	0
30	The resolvin D1 receptor GPR32 transduces inflammation resolution and atheroprotection. Journal of Clinical Investigation, 2021, 131, .	3.9	37
31	Atherosclerosis associated pathways are upregulated in stenotic aortic valves from patients with severe concomitant coronary artery disease. European Heart Journal, 2021, 42, .	1.0	0
32	Gastro-Cardiology: A Novel Perspective for the Gastrocardiac Syndrome. Frontiers in Cardiovascular Medicine, 2021, 8, 764478.	1.1	4
33	Pro-resolving Mediators. , 2021, , 1267-1272.		0
34	Cardiovascular Autonomic Function Changes and Predictors During a 2-Year Physical Activity Program in Rheumatoid Arthritis: A PARA 2010 Substudy. Frontiers in Medicine, 2021, 8, 788243.	1.2	7
35	Cardiovascular Risk Factors and Hemodynamic Measures as Determinants of Increased Arterial Stiffness Following Surgical Aortic Valve Replacement. Frontiers in Cardiovascular Medicine, 2021, 8, 754371.	1.1	11
36	Inverse J-shaped relation between coronary arterial calcium density and mortality in advanced chronic kidney disease. Nephrology Dialysis Transplantation, 2020, 35, 1202-1211.	0.4	20

#	Article	IF	CITATIONS
37	Body mass index and body composition in relation to 14 cardiovascular conditions in UK Biobank: a Mendelian randomization study. European Heart Journal, 2020, 41, 221-226.	1.0	259
38	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal, 2020, 41, 407-477.	1.0	4,210
39	TLR7 Expression Is Associated with M2 Macrophage Subset in Calcific Aortic Valve Stenosis. Cells, 2020, 9, 1710.	1.8	13
40	Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science. Cardiovascular Research, 2020, 116, 2177-2184.	1.8	331
41	Contemporary rationale for non-invasive imaging of adverse coronary plaque features to identify the vulnerable patient:Âa Position Paper from the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology and the European Association of Cardiovascular Imaging. European Heart lournal Cardiovascular Imaging, 2020, 21, 1177-1183.	0.5	29
42	Omega-3 Polyunsaturated Fatty Acids and the Resolution of Inflammation: Novel Therapeutic Opportunities for Aortic Valve Stenosis?. Frontiers in Cell and Developmental Biology, 2020, 8, 584128.	1.8	5
43	Lipoprotein(a) in Alzheimer, Atherosclerotic, Cerebrovascular, Thrombotic, and Valvular Disease. Circulation, 2020, 141, 1826-1828.	1.6	56
44	FADS1 (Fatty Acid Desaturase 1) Genotype Associates With Aortic Valve FADS mRNA Expression, Fatty Acid Content and Calcification. Circulation Genomic and Precision Medicine, 2020, 13, e002710.	1.6	11
45	Omega-3 Polyunsaturated Fatty Acids Decrease Aortic Valve Disease Through the Resolvin E1 and ChemR23 Axis. Circulation, 2020, 142, 776-789.	1.6	44
46	Proteoglycan 4 is Increased in Human Calcified Aortic Valves and Enhances Valvular Interstitial Cell Calcification. Cells, 2020, 9, 684.	1.8	17
47	Aortic Valve Calcium Associates with All-Cause Mortality Independent of Coronary Artery Calcium and Inflammation in Patients with End-Stage Renal Disease. Journal of Clinical Medicine, 2020, 9, 607.	1.0	10
48	Enalapril Influence on Arterial Stiffness in Rheumatoid Arthritis Women: A Randomized Clinical Trial. Frontiers in Medicine, 2020, 6, 341.	1.2	9
49	Semicarbazide-Sensitive Amine Oxidase Increases in Calcific Aortic Valve Stenosis and Contributes to Valvular Interstitial Cell Calcification. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-9.	1.9	21
50	Aortic Stenosis and the TyrosineÂKinaseÂInhibitor Nilotinib inÂChronic Myeloid Leukemia. JACC: CardioOncology, 2020, 2, 123-126.	1.7	6
51	Genetic predisposition to smoking in relation to 14 cardiovascular diseases. European Heart Journal, 2020, 41, 3304-3310.	1.0	83
52	Inflammation and Premature Ageing in Chronic Kidney Disease. Toxins, 2020, 12, 227.	1.5	126
53	Stimulating the Resolution of Inflammation Through Omega-3 Polyunsaturated Fatty Acids in COVID-19: Rationale for the COVID-Omega-F Trial. Frontiers in Physiology, 2020, 11, 624657.	1.3	51
54	Inflammation and its resolution in coronary artery disease: a tightrope walk between omega-6 and omega-3 polyunsaturated fatty acids. Kardiologia Polska, 2020, 78, 93-95.	0.3	10

#	Article	IF	CITATIONS
55	Leukotriene receptors (version 2020.3) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2020, 2020, .	0.2	0
56	Eastern Remedies for Western-type diet induced atherosclerosis. Annals of Translational Medicine, 2020, 8, 258-258.	0.7	1
57	Urinary prostaglandin D2 and E2 metabolites associate with abdominal obesity, glucose metabolism, and triglycerides in obese subjects. Prostaglandins and Other Lipid Mediators, 2019, 145, 106361.	1.0	15
58	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G proteinâ€coupled receptors. British Journal of Pharmacology, 2019, 176, S21-S141.	2.7	519
59	The resolution of inflammation through omega-3 fatty acids in atherosclerosis, intimal hyperplasia, and vascular calcification. Seminars in Immunopathology, 2019, 41, 757-766.	2.8	67
60	Kidney Dysfunction and the Risk of Developing Aortic Stenosis. Journal of the American College of Cardiology, 2019, 73, 305-314.	1.2	59
61	Omegaâ€3 fatty acids, cardiovascular risk, and the resolution of inflammation. FASEB Journal, 2019, 33, 1536-1539.	0.2	61
62	Immunometabolism and atherosclerosis: perspectives and clinical significance: a position paper from the Working Group on Atherosclerosis and Vascular Biology of the European Society of Cardiology. Cardiovascular Research, 2019, 115, 1385-1392.	1.8	58
63	Chemerin inhibits vascular calcification through ChemR23 and is associated with lower coronary calcium in chronic kidney disease. Journal of Internal Medicine, 2019, 286, 449-457.	2.7	26
64	04:21 PM Abstract No. 72 A prospective study evaluating a novel class of software for quantifying successful tissue perfusion during lower extremity endovascular stent placement. Journal of Vascular and Interventional Radiology, 2019, 30, S34-S35.	0.2	0
65	Relationship of Iron Deposition toÂCalcium Deposition in HumanÂAorticÂValve Leaflets. Journal of the American College of Cardiology, 2019, 73, 1043-1054.	1.2	47
66	Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nature Reviews Cardiology, 2019, 16, 389-406.	6.1	684
67	Upregulated Autophagy in Calcific Aortic Valve Stenosis Confers Protection of Valvular Interstitial Cells. International Journal of Molecular Sciences, 2019, 20, 1486.	1.8	16
68	Plasma Phospholipid Fatty Acids, FADS1 and Risk of 15 Cardiovascular Diseases: A Mendelian Randomisation Study. Nutrients, 2019, 11, 3001.	1.7	37
69	Left atrial strain improves estimation of filling pressures in heart failure: a simultaneous echocardiographic and invasive haemodynamic study. Clinical Research in Cardiology, 2019, 108, 703-715.	1.5	51
70	Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology. Cardiovascular Research, 2019, 115, 10-19.	1.8	72
71	The G-protein coupled receptor ChemR23 determines smooth muscle cell phenotypic switching to enhance high phosphate-induced vascular calcification. Cardiovascular Research, 2019, 115, 1557-1566.	1.8	35
72	Dietary patterns, food groups, and incidence of aortic valve stenosis: A prospective cohort study. International Journal of Cardiology, 2019, 283, 184-188.	0.8	14

#	Article	IF	CITATIONS
73	Leukotriene receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	2
74	Formylpeptide receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	0
75	Novel concepts for the role of smooth muscle cells in vascular disease: towards a new smooth muscle cell classification. Cardiovascular Research, 2018, 114, 477-480.	1.8	22
76	Coffee consumption and risk of aortic valve stenosis: A prospective study. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 803-807.	1.1	9
77	Type 1 and type 2 diabetes mellitus and incidence of seven cardiovascular diseases. International Journal of Cardiology, 2018, 262, 66-70.	0.8	140
78	Basic Mechanisms of Atherosclerosis. , 2018, , 45-54.		4
79	Enhanced ventricularâ€arterial coupling during a 2â€year physical activity programme in patients with rheumatoid arthritis: a prospective substudy of the physical activity in rheumatoid arthritis 2010 trial. Journal of Internal Medicine, 2018, 284, 664-673.	2.7	26
80	P5616Left atrial strain improves estimation of filling pressures at rest and during exercise in heart failure. European Heart Journal, 2018, 39, .	1.0	0
81	Resolution of Inflammation Through the Lipoxin and ALX/FPR2 Receptor Pathway Protects Against Abdominal Aortic Aneurysms. JACC Basic To Translational Science, 2018, 3, 719-727.	1.9	38
82	Differential Associations for Salivary Sodium, Potassium, Calcium, and Phosphate Levels with Carotid Intima Media Thickness, Heart Rate, and Arterial Stiffness. Disease Markers, 2018, 2018, 1-12.	0.6	17
83	Opposing Effects on Vascular Smooth Muscle Cell Proliferation and Macrophage-induced Inflammation Reveal a Protective Role for the Proresolving Lipid Mediator Receptor ChemR23 in Intimal Hyperplasia. Frontiers in Pharmacology, 2018, 9, 1327.	1.6	22
84	Lipoxin and Resolvin Receptors Transducing the Resolution of Inflammation in Cardiovascular Disease. Frontiers in Pharmacology, 2018, 9, 1273.	1.6	117
85	Immune-Mediated Mechanisms of Atherosclerosis. , 2018, , 68-76.		1
86	Nut consumption and incidence of seven cardiovascular diseases. Heart, 2018, 104, 1615-1620.	1.2	32
87	P5093Kidney dysfunction is a risk factor for developing aortic stenosis: results from the SCREAM project. European Heart Journal, 2018, 39, .	1.0	0
88	Comparison of right ventricular function after ministernotomy and full sternotomy aortic valve replacement: a randomized study. Interactive Cardiovascular and Thoracic Surgery, 2018, 26, 790-797.	0.5	14
89	Right ventricular mechanics and contractility after aortic valve replacement surgery: a randomised study comparing minimally invasive versus conventional approach. Open Heart, 2018, 5, e000842.	0.9	10
90	Impaired left atrial dynamics and its improvement by guided physical activity reveal left atrial strain as a novel early indicator of reversible cardiac dysfunction in rheumatoid arthritis. European Journal of Preventive Cardiology, 2018, 25, 1106-1108.	0.8	23

#	Article	IF	CITATIONS
91	Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice. European Journal of Preventive Cardiology, 2018, 25, 948-955.	0.8	46
92	Neutrophils recruited by leukotriene B4 induce features of plaque destabilization during endotoxaemia. Cardiovascular Research, 2018, 114, 1656-1666.	1.8	34
93	Future directions for therapeutic strategies in post-ischaemic vascularization: a position paper from European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology. Cardiovascular Research, 2018, 114, 1411-1421.	1.8	19
94	Physical Activity Does Not Reduce Aortic Valve Stenosis Incidence. Circulation Journal, 2018, 82, 2372-2374.	0.7	8
95	ERV1/ChemR23 Signaling Protects Against Atherosclerosis by Modifying Oxidized Low-Density Lipoprotein Uptake and Phagocytosis in Macrophages. Circulation, 2018, 138, 1693-1705.	1.6	106
96	Fetuin A in aortic stenosis and valve calcification: Not crystal clear. International Journal of Cardiology, 2018, 265, 77-78.	0.8	13
97	Cysteinyl-leukotriene pathway as a new therapeutic target for the treatment of atherosclerosis related to obstructive sleep apnea syndrome. Pharmacological Research, 2018, 134, 311-319.	3.1	14
98	Endogenous Calcification Inhibitors in the Prevention of Vascular Calcification: A Consensus Statement From the COST Action EuroSoftCalcNet. Frontiers in Cardiovascular Medicine, 2018, 5, 196.	1.1	82
99	OBSOLETE: Immune-mediated Mechanisms of Atheroslcerosis. , 2018, , .		0
100	Aspirinâ€ŧriggered lipoxin A4 inhibits atherosclerosis progression in apolipoprotein E <sup>â^'/â^'</sup> mice. British Journal of Pharmacology, 2017, 174, 4043-4054.	2.7	89
101	Low salivary resolvin D1 to leukotriene B <sub>4</sub> ratio predicts carotid intima media thickness: A novel biomarker of non-resolving vascular inflammation. European Journal of Preventive Cardiology, 2017, 24, 903-906.	0.8	65
102	Spinal cord stimulation in heart failure: effect on diseaseâ€associated biomarkers. European Journal of Heart Failure, 2017, 19, 283-286.	2.9	5
103	Overall and abdominal obesity and incident aortic valve stenosis: two prospective cohort studies. European Heart Journal, 2017, 38, 2192-2197.	1.0	78
104	Alcohol consumption, cigarette smoking and incidence of aortic valve stenosis. Journal of Internal Medicine, 2017, 282, 332-339.	2.7	33
105	Disease duration of rheumatoid arthritis is a predictor of vascular stiffness. Medicine (United States), 2017, 96, e7862.	0.4	25
106	Omega-3 fatty acids in atherosclerosis and coronary artery disease. Future Science OA, 2017, 3, FSO236.	0.9	41
107	Association of a variant in the gene encoding for ERV1/ChemR23 with reduced inflammation in visceral adipose tissue from morbidly obese individuals. Scientific Reports, 2017, 7, 15724.	1.6	27
108	Biomarkers in Mitral Regurgitation. Progress in Cardiovascular Diseases, 2017, 60, 334-341.	1.6	7

#	Article	IF	CITATIONS
109	Bioactive lipids in aortic valve stenosis—a possible link to atherosclerosis?. Cardiovascular Research, 2017, 113, 1276-1278.	1.8	4
110	NOTCH1 Mutations in Aortic Stenosis: Association with Osteoprotegerin/RANK/RANKL. BioMed Research International, 2017, 2017, 1-10.	0.9	20
111	The inflammatory cytokine interferonâ€gamma inhibits sortilinâ€1 expression in hepatocytes via the JAK/STAT pathway. European Journal of Immunology, 2017, 47, 1918-1924.	1.6	15
112	Iron alters valvular interstitial cell function and is associated with calcification in aortic stenosis. European Heart Journal, 2016, 37, 3532-3535.	1.0	32
113	Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Annals of Internal Medicine, 2016, 165, 161.	2.0	86
114	Chronic adventitial inflammation, vasa vasorum expansion, and 5â€lipoxygenase upâ€regulation in irradiated arteries from cancer survivors. FASEB Journal, 2016, 30, 3845-3852.	0.2	17
115	Valve, Ventricle, and Vessel. Circulation: Cardiovascular Imaging, 2016, 9, e004590.	1.3	2
116	Leukotrienes as Biomarkers of Cardiovascular Disease. , 2016, , 449-466.		0
117	Leukotrienes. , 2016, , 849-857.		0
118	Lipoxygenases and Cardiovascular Diseases. , 2016, , 101-130.		1
119	Hemodynamic outcomes of transcatheter aortic valve implantation with the CoreValve system: an early assessment. Clinical Physiology and Functional Imaging, 2015, 35, 216-222.	0.5	1
120	Novel methodologies for biomarker discovery in atherosclerosis. European Heart Journal, 2015, 36, 2635-2642.	1.0	174
121	Anti-inflammatory therapies for atherosclerosis. Nature Reviews Cardiology, 2015, 12, 199-211.	6.1	315
122	The role of the FPR2/ALX receptor in atherosclerosis development and plaque stability. Cardiovascular Research, 2015, 105, 65-74.	1.8	102
123	Inhibition of indoleamine 2,3-dioxygenase promotes vascular inflammation and increases atherosclerosis in Apoeâ~'/â^' mice. Cardiovascular Research, 2015, 106, 295-302.	1.8	77
124	Regulation of atherosclerotic plaque inflammation. Journal of Internal Medicine, 2015, 278, 462-482.	2.7	70
125	Aspirin-triggered 15-epi-lipoxin A4 signals through FPR2/ALX in vascular smooth muscle cells and protects against intimal hyperplasia after carotid ligation. International Journal of Cardiology, 2015, 179, 370-372.	0.8	50
126	Differential regulation of monocytic expression of leukotriene and lipoxin receptors. Prostaglandins and Other Lipid Mediators, 2015, 121, 138-143.	1.0	11

#	Article	IF	CITATIONS
127	Obstructive sleep apnoea and cardiovascular calcification. Thorax, 2015, 70, 815-816.	2.7	2
128	The leukotriene B4 receptor (BLT) antagonist BIIL284 decreases atherosclerosis in ApoEâ^'/â^' mice. Prostaglandins and Other Lipid Mediators, 2015, 121, 105-109.	1.0	26
129	Leukotrienes as a molecular link between obstructive sleep apnoea and atherosclerosis. Cardiovascular Research, 2014, 101, 187-193.	1.8	31
130	Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation. Journal of Thrombosis and Haemostasis, 2014, 12, 126-137.	1.9	79
131	<i>Mycobacterium bovis </i> <scp>BCG</scp> killed by extended freezeâ€drying induces an immunoregulatory profile and protects against atherosclerosis. Journal of Internal Medicine, 2014, 275, 49-58.	2.7	35
132	Differential association of chronic obstructive pulmonary disease with myocardial infarction and ischemic stroke in a nation-wide cohort. International Journal of Cardiology, 2014, 173, 601-603.	0.8	23
133	Docosahexaenoic acid supplementation modifies fatty acid incorporation in tissues and prevents hypoxia induced-atherosclerosis progression in apolipoprotein-E deficient mice. Prostaglandins Leukotrienes and Essential Fatty Acids, 2014, 91, 111-117.	1.0	19
134	Prosthesis-patient mismatch after transcatheter aortic valve implantation: impact of 2D-transthoracic echocardiography versus 3D-transesophageal echocardiography. International Journal of Cardiovascular Imaging, 2014, 30, 1549-1557.	0.7	8
135	Biomechanical factors in atherosclerosis: mechanisms and clinical implications. European Heart Journal, 2014, 35, 3013-3020.	1.0	359
136	Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7. British Journal of Pharmacology, 2014, 171, 3551-3574.	2.7	173
137	Inhibition of indoleamine 2,3-dioxygenase-mediated tryptophan catabolism accelerates atherosclerosis in hypercholesterolemic mice. Atherosclerosis, 2014, 235, e140.	0.4	0
138	Increased Risk of Cardiovascular Events Associated with TKI Treatment in Chronic Phase Chronic Myeloid Leukemia. Data from Swedish Population-Based Registries. Blood, 2014, 124, 3134-3134.	0.6	6
139	Leukotriene Production Is Increased in Abdominal Obesity. PLoS ONE, 2014, 9, e104593.	1.1	19
140	Leukotrienes. , 2014, , 1-10.		0
141	Eicosanoids and Their Drugs in Cardiovascular Diseases: Focus on Atherosclerosis and Stroke. Medicinal Research Reviews, 2013, 33, 364-438.	5.0	93
142	Transesophageal echocardiography measurements of aortic annulus diameter using biplane mode in patients undergoing transcatheter aortic valve implantation. Cardiovascular Ultrasound, 2013, 11, 5.	0.5	17
143	Valvular osteoclasts in calcification and aortic valve stenosis severity. International Journal of Cardiology, 2013, 168, 2264-2271.	0.8	37
144	Effects of the dual TP receptor antagonist and thromboxane synthase inhibitor EV-077 on human endothelial and vascular smooth muscle cells. Biochemical and Biophysical Research Communications, 2013, 441, 393-398.	1.0	23

#	Article	IF	CITATIONS
145	The leukotriene receptor antagonist montelukast and aortic stenosis. British Journal of Clinical Pharmacology, 2013, 75, 280-281.	1.1	5
146	NOD2-Mediated Innate Immune Signaling Regulates the Eicosanoids in Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2193-2201.	1.1	37
147	Inflammatory mediators in saliva associated with arterial stiffness and subclinical atherosclerosis. Journal of Hypertension, 2013, 31, 2251-2258.	0.3	54
148	Biomechanical factors in the biology of aortic wall and aortic valve diseases. Cardiovascular Research, 2013, 99, 232-241.	1.8	195
149	Urinary Leukotriene E <sub>4</sub> Is Associated with Renal Function but Not with Endothelial Function in Type 2 Diabetes. Disease Markers, 2013, 35, 475-480.	0.6	14
150	Intermittent hypoxia-activated cyclooxygenase pathway: role in atherosclerosis. European Respiratory Journal, 2013, 42, 404-413.	3.1	43
151	Release of leukotriene B4, transforming growth factor-beta1 and microparticles in relation to aortic valve calcification. Journal of Heart Valve Disease, 2013, 22, 782-8.	0.5	9
152	Leukotriene B4 pathway activation and atherosclerosis in obstructive sleep apnea. Journal of Lipid Research, 2012, 53, 1944-1951.	2.0	34
153	Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. European Heart Journal, 2012, 33, 1928-1933.	1.0	70
154	Cysteinyl leukotriene signaling through perinuclear CysLT1 receptors on vascular smooth muscle cells transduces nuclear calcium signaling and alterations of gene expression. Journal of Molecular Medicine, 2012, 90, 1223-1231.	1.7	22
155	Increased transcript level of poly(ADP-ribose) polymerase (PARP-1) in human tricuspid compared with bicuspid aortic valves correlates with the stenosis severity. Biochemical and Biophysical Research Communications, 2012, 420, 671-675.	1.0	15
156	Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. Journal of Allergy and Clinical Immunology, 2012, 129, 702-707.e2.	1.5	100
157	3D TEE With Stereovision for Guidance of the Transcatheter Mitral Valve Repair. JACC: Cardiovascular Imaging, 2012, 5, 1066-1069.	2.3	5
158	Physiopathologie moléculaire et cellulaire du rétrécissement aortique. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2012, 2012, 23-26.	0.0	0
159	Leukotrienes as Modifiers of Preclinical Atherosclerosis?. Scientific World Journal, The, 2012, 2012, 1-6.	0.8	23
160	Epigenetic regulation of 5â€lipoxygenase in the phenotypic plasticity of valvular interstitial cells associated with aortic valve stenosis. FEBS Letters, 2012, 586, 1325-1329.	1.3	22
161	International Union of Basic and Clinical Pharmacology. LXXXIV: Leukotriene Receptor Nomenclature, Distribution, and Pathophysiological Functions. Pharmacological Reviews, 2011, 63, 539-584.	7.1	134
162	The Role of Matrix Metalloproteinases in Atherothrombosis. Current Atherosclerosis Reports, 2011, 13, 162-169.	2.0	84

#	Article	IF	CITATIONS
163	Upregulation of the 5-Lipoxygenase Pathway in Human Aortic Valves Correlates With Severity of Stenosis and Leads to Leukotriene-Induced Effects on Valvular Myofibroblasts. Circulation, 2011, 123, 1316-1325.	1.6	92
164	Leukotrienes and Atherosclerosis. Current Drug Targets, 2010, 11, 882-887.	1.0	44
165	Thromboxane synthase expression and thromboxane A2 production in the atherosclerotic lesion. Journal of Molecular Medicine, 2010, 88, 795-806.	1.7	44
166	Matrix Metalloproteinases in Atherothrombosis. Progress in Cardiovascular Diseases, 2010, 52, 410-428.	1.6	164
167	Differential inflammatory activity across human abdominal aortic aneurysms reveals neutrophilderived leukotriene B4 as a major chemotactic factor released from the intraluminal thrombus. FASEB Journal, 2009, 23, 1376-1383.	0.2	100
168	Altered reactivity to norepinephrine through COX-2 induction by vascular injury in hypercholesterolemic rabbits. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 297, H1882-H1888.	1.5	13
169	Leukotriene Signaling in Atherosclerosis and Ischemia. Cardiovascular Drugs and Therapy, 2009, 23, 41-48.	1.3	108
170	Increased urinary leukotriene E4 excretion in obstructive sleep apnea: Effects of obesity and hypoxia. Journal of Allergy and Clinical Immunology, 2009, 124, 364-370.e2.	1.5	52
171	Specific mediator inhibition by the NO donors SNP and NCX 2057 in the peripheral lung: implications for allergen-induced bronchoconstriction. Respiratory Research, 2009, 10, 46.	1.4	6
172	Leukotriene Receptor Antagonism and the Prevention of Extracellular Matrix Degradation During Atherosclerosis and In-Stent Stenosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 518-524.	1.1	50
173	Inhibitors of the 5-Lipoxygenase Pathway in Atherosclerosis. Current Pharmaceutical Design, 2009, 15, 3116-3132.	0.9	53
174	Inflammatory signaling through leukotriene receptors in atherosclerosis. Current Atherosclerosis Reports, 2008, 10, 244-251.	2.0	35
175	Atherosclerosis, COPD and chronic inflammation. Respiratory Medicine: COPD Update, 2008, 4, 60-65.	0.3	8
176	Cysteinyl-Leukotrienes in Cerebrovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 805-806.	1.1	6
177	5-Lipoxygenase–Activating Protein. Circulation Research, 2007, 100, 946-949.	2.0	107
178	Increased leukotriene concentrations in gingival crevicular fluid from subjects with periodontal disease and atherosclerosis. Atherosclerosis, 2007, 193, 389-394.	0.4	35
179	Leukotriene Receptors: Crucial Components in Vascular Inflammation. Scientific World Journal, The, 2007, 7, 1422-1439.	0.8	40
180	Endothelium-dependent vascular responses induced by leukotriene B4. Prostaglandins and Other Lipid Mediators, 2007, 83, 209-212.	1.0	12

#	Article	IF	CITATIONS
181	The Oral Cavity and Age: A Site of Chronic Inflammation?. PLoS ONE, 2007, 2, e1351.	1.1	24
182	Leukotriene receptors in atherosclerosis. Annals of Medicine, 2006, 38, 493-502.	1.5	99
183	Effect of cold storage on cholinergic responses induced by electrical field stimulation in human bronchi. Pulmonary Pharmacology and Therapeutics, 2006, 19, 297-302.	1.1	4
184	Gamma-glutamyltransferase, leukotrienes, and cardiovascular risk. European Heart Journal, 2006, 28, 269-269.	1.0	4
185	Inhibition of Nitric-Oxide Synthase Enhances Antigen-Induced Contractions and Increases Release of Cysteinyl-Leukotrienes in Guinea Pig Lung Parenchyma: Nitric Oxide as a Protective Factor. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 458-465.	1.3	20
186	Leukotriene B4 signaling through NF-ÂB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 17501-17506.	3.3	219
187	Leukotriene B4is an indirectly acting vasoconstrictor in guinea pig aorta via an inducible type of BLT receptor. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H419-H424.	1.5	23
188	The contractile action of leukotriene B4 in the guinea-pig lung involves a vascular component. British Journal of Pharmacology, 2004, 141, 449-456.	2.7	28
189	Functional characteristics of cysteinyl-leukotriene receptor subtypes. Life Sciences, 2002, 71, 611-622.	2.0	67
190	Pharmacological evidence for a novel cysteinyl-leukotriene receptor subtype in human pulmonary artery smooth muscle. British Journal of Pharmacology, 2002, 137, 1339-1345.	2.7	38
191	Receptor preferences of cysteinyl-leukotrienes in the guinea pig lung parenchyma. European Journal of Pharmacology, 2002, 436, 119-126.	1.7	10
192	Modulation of vascular tone and reactivity by nitric oxide in porcine pulmonary arteries and veins. Acta Physiologica Scandinavica, 2002, 174, 9-15.	2.3	26
193	The Contraction of the Human Pulmonary Artery by LTC4 is Resistant to CYSLT1 Antagonists and Counteracted by Prostacyclin Release. Advances in Experimental Medicine and Biology, 2002, 507, 315-319.	0.8	3
194	Studies of receptors and modulatory mechanisms in functional responses to cysteinyl-leukotrienes in smooth muscle. Acta Physiologica Scandinavica Supplementum, 2002, 648, 1-55.	1.0	5
195	Leukotriene receptors: functional aspects and future targets. Clinical and Experimental Allergy Reviews, 2001, 1, 137-141.	0.3	8
196	An alternative pathway for metabolism of leukotriene D4 : effects on contractions to cysteinyl-leukotrienes in the guinea-pig trachea. British Journal of Pharmacology, 2001, 133, 1134-1144.	2.7	23
197	Antagonist resistant contractions of the porcine pulmonary artery by cysteinyl-leukotrienes. European Journal of Pharmacology, 2000, 401, 381-388.	1.7	29
198	Prostacyclin modulation of contractions of the human pulmonary artery by cysteinyl–leukotrienes. European Journal of Pharmacology, 2000, 401, 389-395.	1.7	47

#	Article	IF	CITATIONS
199	The cysteinyl-leukotriene receptor antagonist BAY u9773 is a competitive antagonist of leukotriene C4 in the guinea-pig ileum. European Journal of Pharmacology, 1996, 317, 107-113.	1.7	24
200	The tyrosine kinase inhibitor nilotinib targets discoidin domain receptor 2 in calcific aortic valve stenosis British Journal of Pharmacology, 0, , .	2.7	5